AHA Scientific Sessions 2026 Abstract·Nov 9Weight-Loss-Enriched Reverse Cardiac Remodeling After Semaglutide and Tirzepatide Initiation on Longitudinal EchocardiographyCohort study of 3,500 peopleTirzepatidePaper
The Journal of Clinical Endocrinology and Metabolism·Oct 19Impact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficienciesNon-randomized trial in 18 peopleMetabolic syndromePaper
Nephron·Sep 15Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature reviewCase reportLiraglutidePaper
Diabetes, Obesity & Metabolism·Jun 9Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor AgonistsCohort study of 68,536 peopleObesityPaper
ADA Scientific Sessions 2026 Abstract·Jun 6Effect of Obesity Management Medications on Physical Function: A Systematic Review and Meta-analysisMeta-analysis of randomized trialsObesityPaper
Obesity Pillars·Mar 20Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approachReviewIndustry & policyPaper
Obesity·Mar 5Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE ApproachReviewIndustry & policyPaper
Drugs·Feb 12Current and Future Pharmacological Interventions for Acquired Hypothalamic ObesityReviewLifestyle interventionsPaper
Ophthalmology Retina·Dec 27Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss TherapiesCohort study of 60,336 peopleAge-related macular degenerationPaper
American Journal of Ophthalmology·Oct 24Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract DevelopmentCohort study in peopleAge-related cataractPaper
JAMA Ophthalmology·Oct 23Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular DegenerationCohort study of 91,408 peopleAge-related macular degenerationPaper
Diabetes, Obesity & Metabolism·Jun 24The effects of anti-obesity medications on bone metabolism: A critical appraisalReviewObesityPaper
Diseases·Apr 22Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative ReviewReviewInterventionsPaper
Cureus·Mar 10Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic ReviewSystematic reviewPhenterminePaper
Molecular Metabolism·Sep 13Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in miceExperiments in miceDietary restrictionPaper
EClinicalMedicine·Mar 20Pharmacotherapy of obesity: an update on the available medications and drugs under investigationReviewObesityPaper
Peptides·Jan 3An update on peptide-based therapies for type 2 diabetes and obesityReviewType 2 diabetesPaper
Journal of Obesity & Metabolic Syndrome·Sep 30Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?ReviewTirzepatidePaper